Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of RP2 alone and in combination with PD1 Blockade in patients with solid tumours
2024-512866-32-00Phase 2Completed
- Sponsor
- Replimune Group, Inc.
- Start
- May 2024
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2 trial of sturlimogene erparepvec in Nonhematologic neoplasms, sponsored by Replimune Group, Inc. Started May 2024; status: completed.
02
Drugs
sturlimogene erparepvec
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-512866-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512866-32-00.